A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit
By Deidre McPhillips, CNN (CNN) — A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients about the change this year, it suggested that there was “another covered medication that’s safe and effective
Continue Reading